290 related articles for article (PubMed ID: 24702826)
41. Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity.
Ramella NA; Schinella GR; Ferreira ST; Prieto ED; Vela ME; Ríos JL; Tricerri MA; Rimoldi OJ
PLoS One; 2012; 7(8):e43755. PubMed ID: 22952757
[TBL] [Abstract][Full Text] [Related]
42. ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity.
Liz MA; Gomes CM; Saraiva MJ; Sousa MM
J Lipid Res; 2007 Nov; 48(11):2385-95. PubMed ID: 17693625
[TBL] [Abstract][Full Text] [Related]
43. Inborn errors of apolipoprotein A-I metabolism: implications for disease, research and development.
Zanoni P; von Eckardstein A
Curr Opin Lipidol; 2020 Apr; 31(2):62-70. PubMed ID: 32022753
[TBL] [Abstract][Full Text] [Related]
44. Cell milieu significantly affects the fate of AApoAI amyloidogenic variants: predestination or serendipity?
Gaglione R; Smaldone G; Di Girolamo R; Piccoli R; Pedone E; Arciello A
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):377-384. PubMed ID: 29174954
[TBL] [Abstract][Full Text] [Related]
45. Two different types of amyloid deposits--apolipoprotein A-IV and transthyretin--in a patient with systemic amyloidosis.
Bergström J; Murphy CL; Weiss DT; Solomon A; Sletten K; Hellman U; Westermark P
Lab Invest; 2004 Aug; 84(8):981-8. PubMed ID: 15146166
[TBL] [Abstract][Full Text] [Related]
46. Effects of a lipid environment on the fibrillogenic pathway of the N-terminal polypeptide of human apolipoprotein A-I, responsible for in vivo amyloid fibril formation.
Monti DM; Guglielmi F; Monti M; Cozzolino F; Torrassa S; Relini A; Pucci P; Arciello A; Piccoli R
Eur Biophys J; 2010 Aug; 39(9):1289-99. PubMed ID: 20182709
[TBL] [Abstract][Full Text] [Related]
47. High-efficient bacterial production of human ApoA-I amyloidogenic variants.
Del Giudice R; Lagerstedt JO
Protein Sci; 2018 Dec; 27(12):2101-2109. PubMed ID: 30291643
[TBL] [Abstract][Full Text] [Related]
48. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene.
Eriksson M; Schönland S; Yumlu S; Hegenbart U; von Hutten H; Gioeva Z; Lohse P; Büttner J; Schmidt H; Röcken C
J Mol Diagn; 2009 May; 11(3):257-62. PubMed ID: 19324996
[TBL] [Abstract][Full Text] [Related]
49. The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils.
Adachi E; Kosaka A; Tsuji K; Mizuguchi C; Kawashima H; Shigenaga A; Nagao K; Akaji K; Otaka A; Saito H
FEBS Lett; 2014 Jan; 588(3):389-94. PubMed ID: 24316228
[TBL] [Abstract][Full Text] [Related]
50. A transgenic mouse model reproduces human hereditary systemic amyloidosis.
Chabert M; Rousset X; Colombat M; Lacasa M; Kakanakou H; Bourderioux M; Brousset P; Burlet-Schiltz O; Liepnieks JJ; Kluve-Beckerman B; Lambert G; Châtelet FP; Benson MD; Kalopissis AD
Kidney Int; 2019 Sep; 96(3):628-641. PubMed ID: 31200944
[TBL] [Abstract][Full Text] [Related]
51. The Apparent Organ-Specificity of Amyloidogenic ApoA-I Variants Is Linked to Tissue-Specific Extracellular Matrix Components.
Del Giudice R; Lindvall M; Nilsson O; Monti DM; Lagerstedt JO
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613763
[TBL] [Abstract][Full Text] [Related]
52. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
53. The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease.
Marchesi M; Parolini C; Valetti C; Mangione P; Obici L; Giorgetti S; Raimondi S; Donadei S; Gregorini G; Merlini G; Stoppini M; Chiesa G; Bellotti V
Biochim Biophys Acta; 2011 Jan; 1812(1):87-93. PubMed ID: 20637862
[TBL] [Abstract][Full Text] [Related]
54. Protein conformational perturbations in hereditary amyloidosis: Differential impact of single point mutations in ApoAI amyloidogenic variants.
Del Giudice R; Arciello A; Itri F; Merlino A; Monti M; Buonanno M; Penco A; Canetti D; Petruk G; Monti SM; Relini A; Pucci P; Piccoli R; Monti DM
Biochim Biophys Acta; 2016 Feb; 1860(2):434-44. PubMed ID: 26515634
[TBL] [Abstract][Full Text] [Related]
55. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.
Hewing B; Parathath S; Barrett T; Chung WK; Astudillo YM; Hamada T; Ramkhelawon B; Tallant TC; Yusufishaq MS; Didonato JA; Huang Y; Buffa J; Berisha SZ; Smith JD; Hazen SL; Fisher EA
Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):779-89. PubMed ID: 24407029
[TBL] [Abstract][Full Text] [Related]
56. Cellular interaction and cytotoxicity of the iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate.
Kuwabara K; Nishitsuji K; Uchimura K; Hung SC; Mizuguchi M; Nakajima H; Mikawa S; Kobayashi N; Saito H; Sakashita N
J Biol Chem; 2015 Oct; 290(40):24210-21. PubMed ID: 26292220
[TBL] [Abstract][Full Text] [Related]
57. Conformation and lipid binding of a C-terminal (198-243) peptide of human apolipoprotein A-I.
Zhu HL; Atkinson D
Biochemistry; 2007 Feb; 46(6):1624-34. PubMed ID: 17279626
[TBL] [Abstract][Full Text] [Related]
58. Insights into the interaction of the N-terminal amyloidogenic polypeptide of ApoA-I with model cellular membranes.
Rusciano G; Pesce G; Zito G; Sasso A; Gaglione R; Del Giudice R; Piccoli R; Monti DM; Arciello A
Biochim Biophys Acta; 2016 Apr; 1860(4):795-801. PubMed ID: 26820473
[TBL] [Abstract][Full Text] [Related]
59. C-terminal sequence of amyloid-resistant type F apolipoprotein A-II inhibits amyloid fibril formation of apolipoprotein A-II in mice.
Sawashita J; Zhang B; Hasegawa K; Mori M; Naiki H; Kametani F; Higuchi K
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):E836-45. PubMed ID: 25675489
[TBL] [Abstract][Full Text] [Related]
60. Conformation and lipid binding of the N-terminal (1-44) domain of human apolipoprotein A-I.
Zhu HL; Atkinson D
Biochemistry; 2004 Oct; 43(41):13156-64. PubMed ID: 15476409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
